| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| M Victoria Barbado, Mayte Medrano, Teresa Caballero-Velázquez, Isabel Álvarez-Laderas, Luis Ignacio Sánchez-Abarca, Estefania García-Guerrero, Jesús Martín-Sánchez, Iván Valle Rosado, José Ignacio Piruat, Pedro Gonzalez-Naranjo, Nuria Eugenia Campillo, Juan Antonio Páez, José Antonio Pérez-Simó. Cannabinoid derivatives exert a potent anti-myeloma activity both in vitro and in vivo. International journal of cancer. vol 140. issue 3. 2017-04-28. PMID:27778331. |
although hematopoietic and immune system show high levels of the cannabinoid receptor cb2, the potential effect of cannabinoids on hematologic malignancies has been poorly determined. |
2017-04-28 |
2023-08-13 |
mouse |
| b' Andr\\xc3\\xa1s Iring, L\\xc3\\xa1szl\\xc3\\xb3 Hricis\\xc3\\xa1k, Zolt\\xc3\\xa1n Beny\\xc3\\xb. CB1 receptor-mediated respiratory depression by endocannabinoids. Respiratory physiology & neurobiology. vol 240. 2017-04-26. PMID:28254562.' |
endocannabinoids (ecs) are bioactive lipid mediators acting on two distinct cannabinoid receptors (cb1 and cb2), which are ubiquitously expressed in many tissues including the respiratory system. |
2017-04-26 |
2023-08-13 |
Not clear |
| Bitya Raphael, Yankel Gabe. The skeletal endocannabinoid system: clinical and experimental insights. Journal of basic and clinical physiology and pharmacology. vol 27. issue 3. 2017-04-20. PMID:26457774. |
this review focuses on the roles of the endocannabinoid system in skeletal biology via the cannabinoid receptors cb1, cb2 and others. |
2017-04-20 |
2023-08-13 |
Not clear |
| Hyewon Yang, Juan Zhou, Christian Lehman. GPR55 - a putative "type 3" cannabinoid receptor in inflammation. Journal of basic and clinical physiology and pharmacology. vol 27. issue 3. 2017-04-20. PMID:26669245. |
g protein-coupled receptor 55 (gpr55) shares numerous cannabinoid ligands with cb1 and cb2 receptors despite low homology with those classical cannabinoid receptors. |
2017-04-20 |
2023-08-13 |
Not clear |
| C Morell, A Bort, D Vara, A Ramos-Torres, N Rodríguez-Henche, I Díaz-Laviad. The cannabinoid WIN 55,212-2 prevents neuroendocrine differentiation of LNCaP prostate cancer cells. Prostate cancer and prostatic diseases. vol 19. issue 3. 2017-04-18. PMID:27324222. |
the aim of this study was to determine the influence of the cannabinoid win 55,212-2 (win, a non-selective cannabinoid cb1 and cb2 receptor agonist) on the ne differentiation of prostate cancer cells. |
2017-04-18 |
2023-08-13 |
Not clear |
| Fabio Arturo Iannotti, Vincenzo Di Marzo, Stefania Petrosin. Endocannabinoids and endocannabinoid-related mediators: Targets, metabolism and role in neurological disorders. Progress in lipid research. vol 62. 2017-04-13. PMID:26965148. |
the endocannabinoid system (ecs) is composed of two g protein-coupled receptors (gpcrs), the cannabinoid cb1 and cb2 receptors, and the two main endogenous lipid ligands of such receptors (also known as the "endocannabinoids"), anandamide and 2-arachidonoyl-glycerol. |
2017-04-13 |
2023-08-13 |
Not clear |
| Ying Kong, Wanchun Wang, Changjie Zhang, Yi Wu, Yang Liu, Xiaorong Zho. Cannabinoid WIN‑55,212‑2 mesylate inhibits ADAMTS‑4 activity in human osteoarthritic articular chondrocytes by inhibiting expression of syndecan‑1. Molecular medicine reports. vol 13. issue 6. 2017-04-06. PMID:27082728. |
in conclusion, to the best of our knowledge, the present study provides the first in vitro evidence supporting that the synthetic cannabinoid win‑55 inhibits adamts‑4 activity in unstimulated and il‑1β‑stimulated human oa articular chondrocytes by decreasing the mrna stability/expression of syndecan‑1 via cb2. |
2017-04-06 |
2023-08-13 |
human |
| Wen-Juan Huang, Wei-Wei Chen, Xia Zhan. Endocannabinoid system: Role in depression, reward and pain control (Review). Molecular medicine reports. vol 14. issue 4. 2017-04-05. PMID:27484193. |
in ancient times, this depression-pain comorbidity was treated using extracts of the cannabis sativa plant, known now as marijuana and the mode of action of Δ9‑tetrahydrocannabinol, the active cannabinoid ingredient of marijuana, has only recently become known, with the identification of cannabinoid receptor type 1 (cb1) and cb2. |
2017-04-05 |
2023-08-13 |
Not clear |
| Peng Liu, Wei Zhang, Shaobo Zhang, Yibao Zhang, Jing Wan. [Progress in study on endocannabinoids and cannabinoid receptors in the treatment for neuropathic pain]. Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences. vol 41. issue 8. 2017-03-29. PMID:27600019. |
exogenous administration of endocannabinoids exerts analgesic effect in different pain models, which is mainly mediated by the cannabinoid cb1 and cb2 receptors. |
2017-03-29 |
2023-08-13 |
Not clear |
| Giorgia Macedonio, Azzurra Stefanucci, Cristina Maccallini, Sako Mirzaie, Ettore Novellino, Adriano Mollic. Hemopressin Peptides as Modulators of the Endocannabinoid System and their Potential Applications as Therapeutic Tools. Protein and peptide letters. vol 23. issue 12. 2017-03-27. PMID:27748182. |
the endocannabinoid system (ecs) is activated when natural arachidonic acid derivatives (endogenous cannabinoids or endocannabinoids) bind as lipophilic messengers to cannabinoid receptors cb1 and cb2. |
2017-03-27 |
2023-08-13 |
rat |
| Arslan Arinc Kayacelebi, Celina Schauerte, Katharina Kling, Jan Herbers, Bibiana Beckmann, Stefan Engeli, Jens Jordan, Alexander A Zoerner, Dimitrios Tsika. Cross-validated stable-isotope dilution GC-MS and LC-MS/MS assays for monoacylglycerol lipase (MAGL) activity by measuring arachidonic acid released from the endocannabinoid 2-arachidonoyl glycerol. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. vol 1047. 2017-03-22. PMID:27511795. |
2-arachidonoyl glycerol (2ag) is an endocannabinoid that activates cannabinoid (cb) receptors cb1 and cb2. |
2017-03-22 |
2023-08-13 |
Not clear |
| Anna Maria Malfitano, Chiara Laezza, Simone Bertini, Daniela Marasco, Tiziano Tuccinardi, Maurizio Bifulco, Clementina Maner. Immunomodulatory properties of 1,2-dihydro-4-hydroxy-2-oxo-1,8-naphthyridine-3-carboxamide derivative VL15. Biochimie. vol 135. 2017-03-21. PMID:28219703. |
1,2-dihydro-4-hydroxy-2-oxo-1,8-naphthyridine-3-carboxamide derivative vl15 has been recently developed as a selective cannabinoid cb2 receptor compound. |
2017-03-21 |
2023-08-13 |
Not clear |
| Anna Maria Malfitano, Chiara Laezza, Simone Bertini, Daniela Marasco, Tiziano Tuccinardi, Maurizio Bifulco, Clementina Maner. Immunomodulatory properties of 1,2-dihydro-4-hydroxy-2-oxo-1,8-naphthyridine-3-carboxamide derivative VL15. Biochimie. vol 135. 2017-03-21. PMID:28219703. |
given the high selectivity of this compound at the cannabinoid cb2 receptor and the well-known protective function of this receptor in neurological disorders with autoimmune component like multiple sclerosis, we assessed the immunomodulatory properties of vl15. |
2017-03-21 |
2023-08-13 |
Not clear |
| Erin M Rock, Nathalie Boulet, Cheryl L Limebeer, Raphael Mechoulam, Linda A Parke. Cannabinoid 2 (CB2) receptor agonism reduces lithium chloride-induced vomiting in Suncus murinus and nausea-induced conditioned gaping in rats. European journal of pharmacology. vol 786. 2017-03-10. PMID:27263826. |
cannabinoid 2 (cb2) receptor agonism reduces lithium chloride-induced vomiting in suncus murinus and nausea-induced conditioned gaping in rats. |
2017-03-10 |
2023-08-13 |
rat |
| Erin M Rock, Nathalie Boulet, Cheryl L Limebeer, Raphael Mechoulam, Linda A Parke. Cannabinoid 2 (CB2) receptor agonism reduces lithium chloride-induced vomiting in Suncus murinus and nausea-induced conditioned gaping in rats. European journal of pharmacology. vol 786. 2017-03-10. PMID:27263826. |
we aimed to investigate the potential anti-emetic and anti-nausea properties of targeting the cannabinoid 2 (cb2) receptor. |
2017-03-10 |
2023-08-13 |
rat |
| Lin-Lin Wang, Rui Zhao, Jiao-Yong Li, Shan-Shan Li, Min Liu, Meng Wang, Meng-Zhou Zhang, Wen-Wen Dong, Shu-Kun Jiang, Miao Zhang, Zhi-Ling Tian, Chang-Sheng Liu, Da-Wei Gua. Pharmacological activation of cannabinoid 2 receptor attenuates inflammation, fibrogenesis, and promotes re-epithelialization during skin wound healing. European journal of pharmacology. vol 786. 2017-03-10. PMID:27268717. |
previous studies showed that cannabinoid 2 (cb2) receptor is expressed in multiple effector cells during skin wound healing. |
2017-03-10 |
2023-08-13 |
mouse |
| Carmen del Río, Carmen Navarrete, Juan A Collado, M Luz Bellido, María Gómez-Cañas, M Ruth Pazos, Javier Fernández-Ruiz, Federica Pollastro, Giovanni Appendino, Marco A Calzado, Irene Cantarero, Eduardo Muño. The cannabinoid quinol VCE-004.8 alleviates bleomycin-induced scleroderma and exerts potent antifibrotic effects through peroxisome proliferator-activated receptor-γ and CB2 pathways. Scientific reports. vol 6. 2017-03-02. PMID:26887982. |
the cannabinoid quinol vce-004.8 alleviates bleomycin-induced scleroderma and exerts potent antifibrotic effects through peroxisome proliferator-activated receptor-γ and cb2 pathways. |
2017-03-02 |
2023-08-13 |
Not clear |
| Benoit Forget, Mihail Guranda, Islam Gamaleddin, Steven R Goldberg, Bernard Le Fol. Attenuation of cue-induced reinstatement of nicotine seeking by URB597 through cannabinoid CB1 receptor in rats. Psychopharmacology. vol 233. issue 10. 2017-02-22. PMID:26864774. |
the endocannabinoid system is composed of endocannabinoids (such as anandamide), their target receptors (cb1 and cb2 receptors, cb1rs and cb2rs), the enzymes that degrade them (fatty-acid-amide-hydrolase (faah) for anandamide), and an endocannabinoid transporter. |
2017-02-22 |
2023-08-13 |
rat |
| Stamatios Theocharis, Constantinos Giaginis, Paraskevi Alexandrou, Jose Rodriguez, Jason Tasoulas, Eugene Danas, Efstratios Patsouris, Jerzy Klijanienk. Evaluation of cannabinoid CB1 and CB2 receptors expression in mobile tongue squamous cell carcinoma: associations with clinicopathological parameters and patients' survival. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. vol 37. issue 3. 2017-02-13. PMID:26459312. |
evaluation of cannabinoid cb1 and cb2 receptors expression in mobile tongue squamous cell carcinoma: associations with clinicopathological parameters and patients' survival. |
2017-02-13 |
2023-08-13 |
Not clear |
| Cui'e Lu, Linyu Shi, Bei Sun, Yu Zhang, Bailing Hou, Yu'e Sun, Zhengliang Ma, Xiaoping G. A Single Intrathecal or Intraperitoneal Injection of CB2 Receptor Agonist Attenuates Bone Cancer Pain and Induces a Time-Dependent Modification of GRK2. Cellular and molecular neurobiology. vol 37. issue 1. 2017-02-13. PMID:26935064. |
the objective of this study was to explore the potential role of g-protein-coupled receptor kinase 2 (grk2) in the progression of cannabinoid 2 receptor (cb2) agonist-induced analgesic effects of bone cancer pain. |
2017-02-13 |
2023-08-13 |
rat |